Nasopharyngeal carcinoma · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Gemcitabine (GC) Variant #01 | — | R 3 933 | 21d | ~7.4 mo | ~27.9 mo | ~6 | ~R 23 595 PFS proxy · indirect | 8 |
Cisplatin and Fluorouracil (CF) Variant #01 | — | R 1 783 | 28d | ~20.1 mo | ~18.6 mo | ~3 | ~R 5 350 PFS proxy · indirect | 3 |
Carboplatin and Fluorouracil Variant #01 | — | R 1 070 | 21d | — | ~7.4 mo | ~2 | ~R 2 140 PFS proxy · indirect | 1 |
Capecitabine monotherapy Variant #01 | — | R 1 039 | 21d | ~35.9 mo | ~15.3 mo | ~2 | ~R 2 077 PFS proxy · indirect | 2 |
Observation Partial | — | — | — | — | — | — | — | 1 |
5 of 5 regimens shown